- The
main subsidiary of POAI partnered with Genomics England for the
groundbreaking UK 100,000 Genomes Project
- POAI
is positioned on the cutting edge of future cancer treatments
- The
company’s AI-driven platforms are improving cancer patient outcomes and
setting a new standard in the industry
For years, cancer treatment has involved human beings
playing the role of guinea pigs. Oncologists have become quite adept at
diagnosing specific types of cancer, but they mostly lack the data to know
which drugs will be most effective in fighting patients’ specific cancer types.
Patients leave doctors’ offices hopeful but worried, gambling their recovery on
the power of the prescription they received. This is the cancer treatment of
today. However, the future of cancer treatment could be transformed with the
innovative technologies of Predictive
Oncology Inc. (NASDAQ: POAI), a company developing highly customizable
assessment methods for cancer patients to guide personalized treatments.
As part of Predictive Oncology’s commitment to determining
the best pathways for more individualized and effective cancer treatment, one
of its main subsidiaries – Helomics – partnered with the UK 100,000 Genomes
Project (“UK100K”) in a research study focused on driving precision medicine to
help conquer ovarian cancer. The UK100K initiative couples whole genome
sequencing of National Health Service (NHS) patients with cancer and other
diseases to rich clinical data on drug treatments and outcomes. Helomics’ study
centers around utilizing this data to continue improving the effectiveness of
its artificial intelligence (AI)-based precision oncology models to drive both
the individualization of therapy (right drug for the right patient) as well as
the discovery of new treatments. Over the long term, Helomics intends to seek
approval to use its precision oncology models as part of the NHS for ovarian
cancer treatment.
“The promise of precision oncology is therapy tailored to
the patient’s own cancer, yet the reality is that while we can identify
alterations in the DNA of the patient’s tumor, most of these mutations are not
actionable with current drugs,” Dr. Mark Collins, chief innovation officer at
Helomics, stated in a news release (http://ibn.fm/SjzNq). “The goal of this project is to
combine genomic profiling of the patient tumor and the drug response of the
patient from the Genomics England data with Helomics’ unique data set,
utilizing the power of machine learning to create a ‘virtual’ model of the
tumor.”
Collins described his team’s ability to use Helomics’ model
to guide oncologists in selecting appropriate drugs to best treat each patient.
Moving forward, the company seeks to partner with pharmaceutical firms to
develop the “next generation” of precision therapies using these models.
“We’re delighted to work with Helomics and its precision
oncology products to maximize the benefits to patients,” added Genomics England
Chief Commercial Officer Joanne Hackett. “Helomics will collaborate with other companies
at the forefront of genomics and technology to ensure that we turn research
findings into treatments, diagnostic, and benefits for patients as soon as
possible.”
As a result of the UK 100,000 Genomes Project, the United
Kingdom became the first nation in the world to apply whole-genome sequencing
at scale in direct health care, as well as providing access to high-quality,
de-identified clinical and genomic data. This data is crucial for improving
outcomes for patients and has established a difference between patients who are
able to beat their cancers and those who are not.
As a result of its valuable data set and increasingly
effective predictive models, Predictive Oncology is on the cutting edge of what
could soon be seen as the norm for cancer treatment.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
